enGene Therapeutics Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
enGene Therapeutics Inc. (ENGN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 12-month period ending 2024-10-31, per its 10-K filed 2024-12-19.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2024-12-19
- enGene Therapeutics Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2024-10-31 was $0.00.
- enGene Therapeutics Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2024-07-31 was $0.00.
- enGene Therapeutics Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2024-04-30 was $0.00.
- enGene Therapeutics Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2024-01-31 was $0.00.
- enGene Therapeutics Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2024 was $0.00.
- enGene Therapeutics Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2023 was $0.00.
- enGene Therapeutics Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2022 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|---|---|---|
| 2024-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | $0.00 derived: sum of 2 quarters · filed 2024-12-19 | $0.00 derived: sum of 3 quarters · filed 2024-12-19 | $0.00 10-K · filed 2024-12-19 |
| 2024-07-31 | $0.00 10-Q · filed 2024-09-10 | $0.00 derived: sum of 2 quarters · filed 2024-09-10 | $0.00 10-Q · filed 2024-09-10 | |
| 2024-04-30 | $0.00 10-Q · filed 2024-06-14 | $0.00 10-Q · filed 2024-06-14 | ||
| 2024-01-31 | $0.00 10-Q · filed 2024-03-11 | |||
| 2023-10-31 | $0.00 10-K · filed 2024-12-19 | |||
| 2022-10-31 | $0.00 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |